Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Glycopeptide carboxamides active against vancomycin-resistant enterococci.

Zweifel MJ, Snyder NJ, Cooper RD, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ.

J Antibiot (Tokyo). 2003 Mar;56(3):289-95.

2.

Gene disruption studies of penicillin-binding proteins 1a, 1b, and 2a in Streptococcus pneumoniae.

Hoskins J, Matsushima P, Mullen DL, Tang J, Zhao G, Meier TI, Nicas TI, Jaskunas SR.

J Bacteriol. 1999 Oct;181(20):6552-5.

3.

Enzymatic deacylation of teicoplanin followed by reductive alkylation: synthesis and antibacterial activity of new glycopeptides.

Snyder NJ, Cooper RD, Briggs BS, Zmijewski M, Mullen DL, Kaiser RE, Nicas TI.

J Antibiot (Tokyo). 1998 Oct;51(10):945-51.

4.

Novel glycopeptide antibiotics: N-alkylated derivatives active against vancomycin-resistant enterococci.

Rodriguez MJ, Snyder NJ, Zweifel MJ, Wilkie SC, Stack DR, Cooper RD, Nicas TI, Mullen DL, Butler TF, Thompson RC.

J Antibiot (Tokyo). 1998 Jun;51(6):560-9.

5.

Tripeptide LY301621 and its diastereomers as methicillin potentiators against methicillin resistant Staphylococcus aureus

Eid CN, Halligan NG, Nicas TI, Mullen DL, Butler TF, Loncharich RJ, Paschal JW, Schofield CJ, Westwood NJ, Cheng L.

J Antibiot (Tokyo). 1997 Mar;50(3):283-5. No abstract available.

6.

Tripeptide LY301621 and its diastereomers as methicillin potentiators against methicillin resistant Staphylococcus aureus.

Eid CN, Halligan NG, Nicas TI, Mullen DL, Butler TF, Loncharich RJ, Paschal JW, Schofield CJ, Westwood NJ, Cheng L.

J Antibiot (Tokyo). 1997 Mar;50(3):283-5. No abstract available.

7.

Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Zweifel MJ, Wilkie SC, Rodriguez MJ, Thompson RC, Cooper RD.

Antimicrob Agents Chemother. 1996 Sep;40(9):2194-9.

8.

Reductive alkylation of glycopeptide antibiotics: synthesis and antibacterial activity.

Cooper RD, Snyder NJ, Zweifel MJ, Staszak MA, Wilkie SC, Nicas TI, Mullen DL, Butler TF, Rodriguez MJ, Huff BE, Thompson RC.

J Antibiot (Tokyo). 1996 Jun;49(6):575-81.

9.

Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

Nicas TI, Mullen DL, Flokowitsch JE, Preston DA, Snyder NJ, Stratford RE, Cooper RD.

Antimicrob Agents Chemother. 1995 Nov;39(11):2585-7. Erratum in: Antimicrob Agents Chemother 1996 May;40(5):1330.

10.

In-vitro synergy and mechanism of interaction between vancomycin and ciprofloxacin against enterococcal isolates.

Unal S, Flokowitsch J, Mullen DL, Preston DA, Nicas TI.

J Antimicrob Chemother. 1993 May;31(5):711-23.

PMID:
8335499
11.

Financing catastrophic health care costs.

Mullen DL.

Wis Med J. 1991 May;90(5):208, 210. No abstract available.

PMID:
1897234
12.

6-substituted 1,3,4,5-tetrahydrobenz[cd]indol-4-amines: potent serotonin agonists.

Flaugh ME, Mullen DL, Fuller RW, Mason NR.

J Med Chem. 1988 Sep;31(9):1746-53.

PMID:
2457705
13.

Juvenile papillomatosis (Swiss cheese disease) of the breast.

Rosen PP, Cantrell B, Mullen DL, DePalo A.

Am J Surg Pathol. 1980 Feb;4(1):3-12.

PMID:
7361994
14.

Acute peripheral consolidation of the lung.

Heelan RT, Mullen DL.

Clin Bull. 1977;7(2):70-1. No abstract available.

PMID:
902404
15.

Squamous cell carcinoma of the skin and lip in renal homograft recipients.

Mullen DL, Silverberg SG, Penn I, Hammond WS.

Cancer. 1976 Feb;37(2):729-34.

PMID:
766948

Supplemental Content

Loading ...
Support Center